On 05 November 2019, Pintec Technology Holdings Limited (NASDAQ: PT) settled plunge of -8.50% in recent trading period with closing price of $0.87. The company’s last traded volume of 117329 shares vs to an average volume of 197.13K shares. The volatility in the previous week has experienced by 14.85% and observed of 15.79% in the previous month. 0.60% ownership is held by institutional investors while insiders hold ownership of 4.03%.
Proteostasis Therapeutics, Inc. (PTI) recently reported completion of enrollment in the Company’s global, multicenter, randomized, placebo-controlled, 28-day, Phase 2 study evaluating its proprietary cystic fibrosis transmembrane conductance regulator (CFTR) modulator combinations in F508del homozygous and heterozygous CF subjects.
“We are working hard to introduce the power of choice to the CF community and the completion of enrollment in our global Phase 2 study is an important step forward to completing that mission. We heard loud and clear at our recently hosted Cystic Fibrosis Summit, as well as at the last week’s North American CF Conference, that the community urgently demands options to address the inequity in access, variability in clinical response and genetic disparity amongst people with CF,” stated Geoffrey Gilmartin, M.D., M.M.Sc., Chief Medical Officer of Proteostasis. “Due to this strong demand for options and additional trials from the patient and medical community, we’re happy to announce that we now expect top-line data from the Phase 2 study later this quarter.”
Pintec Technology Holdings Limited has price to cash ratio of 0.67. In the trailing 12 months period, return on assets ratio of the Company was 0.80% and return on equity ratio was 10.30% while its return on investment ratio was -0.80%. PT price lost at -25.91% from 20-Days Simple Moving Average, plunged at -53.35% from 50-Days Simple Moving Average and settled at -85.56% from 200 Days Simple Moving Average.